Over the years, the Departments of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center have become leaders in the research and treatment of mantle cell lymphoma (MCL). Our physicians and scientists are the trailblazers in research and development of therapies for this rare but pernicious form of non-Hodgkin lymphoma. We are a major referral center for physicians all over the country and around the world; in fact, our clinic treats more patients with MCL than any other major cancer center in the country.
MCL serves as a model for understanding and treating B cell malignancies. In the majority of cases it is responsive to frontline therapy; however, many patients have disease relapse and eventually chemotherapy resistance. Although, MCL is uncommon, novel therapies can be tested in a small number of patients, making clinical studies to gather data and analyze the results more efficient and allowing for a more rapid translation of drugs from “bench to bedside.”
While it can be difficult to conduct clinical trials for rare diseases, such as MCL – and for patients with the disease to find treatment centers -- MD Anderson has become the first choice. Building upon this success, our current research program has gathered an outstanding core group of bench scientists and translational researchers to work in tandem to our already-acclaimed clinical investigators.
With the support of the institution, we have established the Mantle Cell Lymphoma Program of Excellence, which includes investigators from the Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy departments.